Multiple Myeloma, Phase III
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Volunteers
Health Professionals
What is the purpose of this trial?
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alexis Walker
- Alison Johnson
- Andrea Brennan
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- Brooke Chaves
- Catherine Wei, MD
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Emily Collier, MD
- Erica Stevens
- Harold Tara Jr, MD
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Leena Rahmat
- M. Sung Lee, MD
- Madeline Santiago
- Michael Cohenuram, MD
- Natalia Neparidze, MD
- Neal Fischbach, MD
- Noffar Bar, MD
- Pawan Karanam, MD
- Renee Moye
- Sabrina Browning, MD
- Sara Anastasio, RN
- Sarah Carlson
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Tara Anderson
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated04/05/2024
- Study HIC#2000033033